Aberrant CDK4 Amplification in Refractory Rhabdomyosarcoma as Identified by Genomic Profiling
Adult
Male
0301 basic medicine
Comparative Genomic Hybridization
Chromosomes, Human, Pair 12
Genome, Human
Gene Expression Profiling
Cyclin-Dependent Kinase 4
Proto-Oncogene Mas
Article
03 medical and health sciences
Rhabdomyosarcoma
Disease Progression
Humans
Neoplasm Metastasis
Tomography, X-Ray Computed
DOI:
10.1038/srep03623
Publication Date:
2014-01-10T10:09:10Z
AUTHORS (14)
ABSTRACT
AbstractRhabdomyosarcoma (RMS) is the most commonly occurring type of soft tissue tumor in children. However, it is rare in adults and therefore, very little is known about the most appropriate treatment strategy for adult RMS patients. We performed genomic analysis of RMS cells derived from a 27-year-old male patient whose disease was refractory to treatment. A peritoneal seeding nodule from the primary tumor, pleural metastases, malignant pleural effusion and ascites obtained during disease progression, were analyzed. Whole exome sequencing revealed 23 candidate variants and 10 of 23 mutations were validated by Sanger sequencing. Three of 10 mutations were present in both primary and metastatic tumors and 3 mutations were detected only in metastatic specimens. Comparative genomic hybridization array analysis revealed prominent amplification in the 12q13–14 region and more specifically, the CDK4 proto-oncogene was highly amplified. ALK overexpression was observed at both protein and RNA levels. However, an ALK fusion assay using NanoString technology failed to show any ALK rearrangements. Little genetic heterogeneity was observed between primary and metastatic RMS cells. We propose that CDK4, located at 12q14, is a potential target for drug development for RMS treatment.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (36)
CITATIONS (28)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....